Aortic Stenosis Market Set for Significant Expansion by 2032, Boosted by Technological Advancements and FDA Nod for Edwards TAVR in Asymptomatic Cases | DelveInsight

The Aortic Stenosis market is progressing steadily, driven by the increasing prevalence of the disease, advancements in minimally invasive therapies, and growing adoption of transcatheter aortic valve replacement (TAVR). In a pivotal regulatory milestone, Edwards Lifesciences has received FDA approval for the use of its TAVR system in patients with asymptomatic severe aortic stenosis, marking a significant step forward in early intervention.
DelveInsight's latest 7MM report, "Aortic Stenosis Market Report [https://www.delveinsight.com/report-store/aortic-stenosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]", provides in-depth analysis of market trends, epidemiological insights, and the emerging therapeutic landscape. Covering the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, the report delivers strategic foresight into forecasted growth, unmet needs, and key developments shaping the future of the Aortic Stenosis market.

Some of the Key Facts of the Aortic Stenosis Market Report:

- The total aortic stenosis market size is estimated to grow with a significant CAGR during the study period (2019-2032).

- In 2019, the global prevalence of calcific aortic valve disease (CAVD), which includes AS, was approximately 9.4 million cases, marking a 443% increase from 1990.

- The global incidence of CAVD rose by 351% over the past 30 years, from 130,821 cases in 1990 to 589,637 cases in 2019.

- The prevalence of AS increases with age, rising from less than 50 cases per 100,000 in individuals aged 25-49 years to over 1,300 cases per 100,000 in those aged 80 years or older.

- In May 2025, IGI, a clinical-stage biotech company specializing in multispecifics Trademark for oncology, announced that the FDA granted Fast Track designation for ISB 2001. This designation is for treating adult patients with relapsed or refractory multiple myeloma (RRMM) who have failed at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody.

- In May 2025, Edwards Lifesciences announced FDA approval of its SAPIEN 3 TAVR platform for treating severe aortic stenosis in asymptomatic patients, the first such approval for this population.

- In October 2024, AccurKardia announced that its ECG-based AI screening software for Aortic Valve Stenosis (AVS) has received Breakthrough Device Designation from the FDA.

- Leading Aortic Stenosis therapies include Pelacarsen, Evogliptin, HRS-1893, HS-10511, HRS-1893, Sotagliflozin, Aficamten, Mavacamten, Aficamten, Mavacamten, Trientine, Inclisiran, and others.

- Leading companies in the Aortic Stenosis market include Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, CryoLife, Braile Biomedica, JenaValve Technology, Meril Life Sciences, Micro Interventional Devices, and others.

To know in detail about the aortic stenosis market outlook, drug uptake, treatment scenario, and epidemiology trends, click here: Aortic Stenosis Market Forecast [https://www.delveinsight.com/report-store/aortic-stenosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Aortic Stenosis Overview

Aortic stenosis (AS) is a progressive cardiovascular condition characterized by the narrowing of the aortic valve opening, which restricts blood flow from the left ventricle to the aorta and onward to the rest of the body. This narrowing often results from age-related calcification, congenital heart defects (such as a bicuspid aortic valve), or rheumatic fever. As the valve becomes increasingly stiff and narrowed, the heart must work harder to pump blood, eventually leading to symptoms like chest pain, fatigue, shortness of breath, and, in advanced stages, heart failure.

Although the early stages of AS may be asymptomatic, the condition can progress rapidly. Diagnosis typically involves a physical exam, echocardiography, and other cardiac imaging techniques. Treatment depends on the severity and symptoms and ranges from regular monitoring to surgical or transcatheter aortic valve replacement (TAVR) in severe cases. With recent advancements, such as FDA approval of TAVR for asymptomatic severe AS patients, treatment is becoming more accessible and less invasive, improving outcomes for high-risk and elderly populations.

Get a free sample for the aortic stenosis market report:https://www.delveinsight.com/report-store/aortic-stenosis-market [https://www.delveinsight.com/report-store/aortic-stenosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Aortic Stenosis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Download the report to understand which factors are driving aortic stenosis epidemiology trends at Aortic Stenosis Epidemiology Forecast [https://www.delveinsight.com/report-store/aortic-stenosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Aortic Stenosis Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the rate of uptake of the potential drugs recently launched in the aortic stenosis market or expected to be launched during the study period. The analysis covers the aortic stenosis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the aortic stenosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent collaborations, acquisitions, mergers, licensing, patent details, and other information for emerging therapies.

Aortic Stenosis Market Strengths

- The development of innovative treatments, such as transcatheter aortic valve replacement (TAVR), has significantly improved patient outcomes, boosting market growth.

- The increasing prevalence of aortic stenosis, particularly in the elderly population, is driving demand for effective treatment solutions.

Aortic Stenosis Market Weaknesses

- The cost of advanced therapies, like TAVR, remains high, limiting accessibility for some patient populations and potentially hindering broader market adoption.

- Aortic stenosis often goes undiagnosed in its early stages due to asymptomatic presentation, leading to delays in treatment and impacting market growth.

Scope of the Aortic Stenosis Market Report

- Study Period: 2019-2032

- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

- Key Aortic Stenosis Companies: Edwards Lifesciences, Medtronic, Abbott, Boston Scientific, LivaNova, CryoLife, Braile Biomedica, JenaValve Technology, Meril Life Sciences, Micro Interventional Devices, and others.

- Key Aortic Stenosis drugs: Pelacarsen, Evogliptin, HRS-1893, HS-10511, HRS-1893, Sotagliflozin, Aficamten, Mavacamten, Aficamten, Mavacamten, Trientine, Inclisiran, and others.

- Aortic Stenosis Therapeutic Assessment: Aortic Stenosis currently marketed, and Aortic Stenosis emerging therapies

- Aortic Stenosis Market Dynamics: Aortic Stenosis market drivers and Aortic Stenosis market barriers

- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

- Aortic Stenosis Unmet Needs, KOL's views, Analyst's views, Aortic Stenosis Market Access and Reimbursement

To learn more about the key players and advancements in the aortic stenosis treatment landscape, visit the Aortic Stenosis Market Analysis Report [https://www.delveinsight.com/report-store/aortic-stenosis-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=jpr]

Table of Contents

1. Aortic Stenosis Market Report Introduction

2. Executive Summary for Aortic Stenosis

3. SWOT analysis of Aortic Stenosis

4. Aortic Stenosis Patient Share (%) Overview at a Glance

5. Aortic Stenosis Market Overview at a Glance

6. Aortic Stenosis Disease Background and Overview

7. Aortic Stenosis Epidemiology and Patient Population

8. Country-Specific Patient Population of Aortic Stenosis

9. Aortic Stenosis Current Treatment and Medical Practices

10. Aortic Stenosis Unmet Needs

11. Aortic Stenosis Emerging Therapies

12. Aortic Stenosis Market Outlook

13. Country-Wise Aortic Stenosis Market Analysis (2019-2032)

14. Aortic Stenosis Market Access and Reimbursement of Therapies

15. Aortic Stenosis Market Drivers

16. Aortic Stenosis Market Barriers

17. Aortic Stenosis Appendix

18. Aortic Stenosis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefit from market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Jatin Vimal
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=aortic-stenosis-market-set-for-significant-expansion-by-2032-boosted-by-technological-advancements-and-fda-nod-for-edwards-tavr-in-asymptomatic-cases-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.